(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.47%) $27.23
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $7.33
Utstedt: 14 feb 2024 @ 19:17
Avkastning: 44.20%
Forrige signal: feb 14 - 15:30
Forrige signal:
Avkastning: 6.23 %
Live Chart Being Loaded With Signals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases...
Stats | |
---|---|
Dagens volum | 193 217 |
Gjennomsnittsvolum | 475 155 |
Markedsverdi | 273.83M |
EPS | $0 ( 2024-03-06 ) |
Neste inntjeningsdato | ( $-1.080 ) 2024-05-08 |
Last Dividend | $0.0690 ( 2017-09-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.740 |
ATR14 | $0.0200 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-26 | Weiner David B. | Buy | 972 | Common Stock |
2024-02-26 | Weiner David B. | Buy | 972 | Common Stock |
2024-02-26 | Weiner David B. | Buy | 972 | Common Stock |
2024-02-26 | Weiner David B. | Sell | 972 | Restricted Stock Unit |
2024-02-26 | Weiner David B. | Sell | 972 | Restricted Stock Unit |
INSIDER POWER |
---|
61.43 |
Last 100 transactions |
Buy: 3 683 868 | Sell: 932 723 |
Volum Korrelasjon
Inovio Pharmaceuticals Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
AKTX | 0.966 |
LSXMA | 0.961 |
LSXMK | 0.961 |
STRO | 0.95 |
TUEM | 0.948 |
ASPU | 0.946 |
OPHC | 0.943 |
CMLS | 0.942 |
WATT | 0.942 |
AADI | 0.941 |
10 Mest negative korrelasjoner | |
---|---|
CPTA | -0.952 |
SGEN | -0.946 |
RAM | -0.936 |
GPACU | -0.936 |
NVSA | -0.936 |
COCO | -0.934 |
MLAI | -0.932 |
PESI | -0.928 |
PTOC | -0.928 |
FRSG | -0.927 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Inovio Pharmaceuticals Korrelasjon - Valuta/Råvare
Inovio Pharmaceuticals Økonomi
Annual | 2023 |
Omsetning: | $832 010 |
Bruttogevinst: | $-2.67M (-321.09 %) |
EPS: | $-6.09 |
FY | 2023 |
Omsetning: | $832 010 |
Bruttogevinst: | $-2.67M (-321.09 %) |
EPS: | $-6.09 |
FY | 2022 |
Omsetning: | $10.26M |
Bruttogevinst: | $4.77M (46.44 %) |
EPS: | $-14.47 |
FY | 2021 |
Omsetning: | $1.77M |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-1.450 |
Financial Reports:
No articles found.
Inovio Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0690 | 2017-06-28 |
Last Dividend | $0.0690 | 2017-09-28 |
Next Dividend | $0 | N/A |
Payout Date | 2017-10-16 | |
Next Payout Date | N/A | |
# dividends | 4 | -- |
Total Paid Out | $0.276 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.17 | -- |
Div. Sustainability Score | 2.18 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.449 | -- |
Year | Amount | Yield |
---|---|---|
2017 | $0.276 | 3.90% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 3 430.55 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 16.50 | 1.200 | 10.00 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 18.29 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.60 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.47 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.336 | 1.500 | 9.24 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.175 | -1.500 | 7.09 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -241.59 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -5.80 | 2.00 | -1.932 | -3.86 | [0 - 30] |
freeCashFlowPerShareTTM | -5.81 | 2.00 | -2.90 | -5.81 | [0 - 20] |
debtEquityRatioTTM | 0.257 | -1.500 | 8.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -38.10 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -173.00 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -4.37 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00481 | 0.800 | -3.30 | -2.64 | [0.5 - 2] |
Total Score | 2.18 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 0.0844 | 1.000 | -0.0925 | 0 | [1 - 100] |
returnOnEquityTTM | 18.29 | 2.50 | 10.00 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -5.81 | 2.00 | -1.936 | -5.81 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -5.80 | 2.00 | -1.932 | -3.86 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0000652 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -158.77 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.283 |
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.